The renin/angiotensin system (RAS) is a tonic anti-drop regulator of a
rterial blood pressure in many teleosts. In trout, angiotensin II (ANG
II) has no direct constrictor effect on large arteries or veins and t
he identity of specific cardiovascular presser effecters is unknown. P
otential targets of angiotensin activation were examined in the presen
t experiments using perfused organs and isolated tissues from the rain
bow trout Oncorhynchus mykiss. Perfused gill (arches 2 and 3), perfuse
d skeletal muscle-kidney (via the dorsal aorta; PDA) and perfused spla
nchnic (via the celiacomesenteric; PCM) circulations vasoconstrict in
response to salmonid ANG II in a dose-dependent manner. ANG II was sig
nificantly (P less than or equal to 0.05) more potent in the PCM than
in the PDA, and both preparations were more responsive than the gills:
pD(2)=8.0+/-0.20 (10) for PCM; pD(2)=7.5+/-0.07 (13) for PDA; pD(2)=6
.9+/-0.21 (8) for gill arch 3; pD(2)=6.7+/-0.23 (8) for gill arch 2; m
ean +/- S.E.M. (N), respectively. Salmonid angiotensin I (ANG I) also
produced a dose-dependent constriction of the PDA and PCM. Angiotensin
converting enzyme (ACE) activated nearly 100% of ANG I to ANG II in a
single pass through the PDA, whereas PCM conversion was estimated to
be less than 10%. Inhibitors of adrenergic constriction partially prev
ented ANG II responses in the PDA but did not affect PCM responses. AN
G II did not affect paced rings of ventricular muscle in the presence
of high or low [Ca2+] or epinephrine concentrations, nor did it have a
ny inotropic or chronotropic effects in the in situ perfused heart. Re
d blood cell swelling was unaffected by ANG II. Similarly, the effects
of ANG II on gut, urinary bladder and gall bladder smooth muscle were
negligible or non-existent; thus, an increase in splanchnic resistanc
e due to extravascular compression can be discounted.